| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $10.12 | - | - |
| Q4'26 | $11.29 | $0.61 | -94.6% |
| Q3'25 | $5.78 | $4.36 | -24.5% |
| Q2'25 | $15.47 | $14.75 | -4.7% |
| Q1'25 | $12.81 | $12.52 | -2.3% |
| Q4'24 | $19.38 | $21.39 | +10.4% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $274.8B | - | - |
| Q4'26 | $252.2B | $239.6B | -5.0% |
| Q3'25 | - | $247.8B | - |
| Q2'25 | - | $247.7B | - |
| Q1'25 | - | $236.5B | - |
| Q4'24 | - | $280.2B | - |
Market Data
BABA is currently trading at $112.53, giving Alibaba Group Holding Limited a market cap of 264.23B and a P/E ratio of 16.9. Today's range spans $111.14–$115.58, with shares opening at $113.24 and moving up $0.19 (0.2%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 79/100.
Over the past year BABA has traded between $91.99 and $192.67 - the current price is +22.3% off the 52-week low and -41.6% from the high. 48 analysts cover the stock with a Buy consensus and a mean 12-month target of $190.23 (range $92.11–$241.75), implying upside of +69.0%.
The technical picture for BABA is mixed - score 36/100, HOLD, with the stock at $112.53 (in the lower half of its 52-week range) and sentiment bullish at 79/100. For a large-cap in Consumer Cyclical with 264.23B in capitalization The current P/E ratio stands at 16.9., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $91.99–$192.67. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.
Portfolio construction in Consumer Cyclical often uses large-cap names like BABA as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 36/100 (HOLD) at $112.53 (in the lower half of its 52-week range) and bullish sentiment (79/100) frame the position as a catalyst play within the $91.99–$192.67 annual range rather than a directional bet.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).